Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly and Company (LLY) reported third-quarter 2026 revenue of $24.397 billion, up 39% from $17.601 billion a year earlier, and net income of $6.451 billion, up 16% from $5.583 billion. Diluted earnings per share were $7.22, versus $6.21. Revenue growth was driven primarily by higher volume, led by Mounjaro and Zepbound, partly offset by lower realized prices; gross margin was 83.9% of revenue, compared with 82.9%.
For the first nine months of 2026, revenue was $67.170 billion and net income was $20.942 billion. Quarterly acquired in-process research and development charges were $4.181 billion, primarily related to the AtaiBeckley and Curevo acquisitions. Lilly acquired Merida in October for up to $2.9 billion, including upfront and potential clinical and regulatory milestone payments. It declared a fourth-quarter dividend of $1.73 per share, payable December 10, 2026, to shareholders of record November 13, 2026. Cash and equivalents were $4.9 billion and total debt was $49.5 billion as of September 30, 2026; management said available resources were sufficient for existing and planned capital requirements.
Eli Lilly and Company (LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, as volume rose 53% and realized prices fell 15%; Mounjaro and Zepbound were primary drivers. Revenue included approximately $900 million of benefits, mainly $410 million of Jardiance milestones and favorable rebate and discount estimate adjustments; Lilly said no further Jardiance milestones remain.
Reported net income was $6.451 billion and diluted EPS was $7.22, both up 16%; non-GAAP net income was $6.679 billion, up 6%, and non-GAAP diluted EPS was $7.48, up 7%. Both EPS measures included $4.57 per share of acquired IPR&D charges, versus $0.71 a year earlier. Lilly raised 2026 revenue guidance to $91.0–$92.0 billion from $85–$87 billion, and updated non-GAAP EPS guidance to $35.00–$36.00 from $35.50–$36.50. The company said a $4.07 midpoint increase in underlying non-GAAP EPS guidance was more than offset by $4.57 associated with Q3 acquired IPR&D charges.
Lilly completed the AtaiBeckley acquisition during Q3 and completed the Merida Biosciences acquisition after quarter-end. Regulatory progress included U.S. FDA approval of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes, approval of Onswik for adults with type 2 diabetes, and expanded Jaypirca use for adults with untreated CLL or SLL.
Eli Lilly & Co reported a direct holding of 1,104,558 Lycia Therapeutics common shares issuable upon mandatory conversion of convertible preferred stock in Lycia’s initial public offering. The reported amount excludes additional common shares Eli Lilly purchased in the offering, which were not known when the information was reported. After giving effect to the offering’s closing, including that purchase, Eli Lilly will cease to be a 10% owner and will have no further Section 16 reporting obligations.
Eli Lilly & Co. director Gabrielle Sulzberger acquired 3.9976 shares of common stock on October 19, 2026, at a reported price of $1,240.34 per share. At her election, the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service. Her reported direct holdings after the transaction were 3,016.4449 shares.
Eli Lilly & Co. director Juan R. Luciano reported an award acquisition of 12.8325 shares of common stock on October 19, 2026. The transaction lists a per-share price of $1,240.3400. The shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following his separation from service. His reported direct position after the transaction was 16,969.6463 shares.
Eli Lilly & Co. director J. Erik Fyrwald reported acquiring 8 shares of common stock on October 19, 2026, at a reported $1,240.34 per share. At his election, the acquired shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares following his separation from service. His reported direct position following the transaction was 75,544 shares.
Eli Lilly & Co. director Ralph Alvarez acquired 10 shares of common stock on October 19, 2026, at a reported price of $1,240.3400 per share. The shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock following his separation from service. His direct common-stock holdings following the acquisition were 55,848 shares. A separate reported holding lists 758 common shares indirectly held by a trust; Alvarez disclaims beneficial ownership except to the extent of his pecuniary interest.
Eli Lilly and Company (LLY) reporting person Lilly Endowment, Inc. reported beneficial ownership of 90,066,978 common shares, or 9.6%, as of September 30, 2026. Lilly Endowment reported sole voting power and sole dispositive power over all 90,066,978 shares, with no shared voting or dispositive power.
The percentage is based on 941,357,065 Eli Lilly shares outstanding as of August 3, 2026. None of Lilly Endowment’s shares were deemed beneficially owned through a right to acquire shares.
Eli Lilly and Company (LLY) shareholder Lilly Endowment, Inc. reported a proposed sale of 305,000 common shares through Fidelity Capital Markets, with an aggregate market value of $368,665,700 and an approximate sale date of October 15, 2026. The notice lists 941,357,065 shares outstanding and was signed by Diane M. Stenson, Vice President and Treasurer.
Eli Lilly & Co (LLY), listed as a ten percent owner reporting person for TRex Bio, reported direct holdings of 5,480,872 shares of TRex Bio common stock as of October 8, 2026. The reported shares comprise 4,605,872 shares issuable upon mandatory conversion of convertible preferred stock and 875,000 shares being purchased in TRex Bio's initial public offering.